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Supplementary Figure 1 
 
Supplementary Figure 1: Correlation between percentage changes in PD markers at on-treatment 
biopsy after treatment with a) AZD9496 and b) fulvestrant, by individual patient. Blue line represents 
the line of best fit by linear regression and shaded areas represent 80% CIs.  
CI: confidence interval; ER: estrogen receptor; PD: pharmacodynamic; PR: progesterone receptor  
R: correlation coefficient 
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Supplementary Figure 2 
a)  
 
Supplementary Figure 2: Pharmacodynamic marker percentage change by patient after receiving  
(a) AZD9496 or (b) fulvestrant. Each row represents the same patient. Right-hand ‘Day’ column 
represents the day of biopsy for each patient. 
ER: estrogen receptor; PR: progesterone receptor 
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Supplementary Figure 3 
 
 
Supplementary Figure 3:  Plasma concentration of AZD9496, predicted versus observed. AZD9496 
plasma concentration during current study (solid dots) compared with the predicted AZD9496 
concentration based on the previous Phase 1 study1 (hollow dots). Line represents the median 
prediction and the shaded area represents 95% CIs.  
AUC: area under the concentration–time curve; CI: confidence interval; Cmax: maximum plasma 
concentration; SD: standard deviation 
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Supplementary Figure 4 
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Supplementary figure 4: PK/PD relationships at on-treatment biopsy between a) AZD9496 plasma 
concentration and ER percentage change from baseline, b) AZD9496 plasma concentration and PR 
percentage change from baseline, c) AZD9496 plasma concentration and Ki-67 percentage change 
from baseline, and d) observed fulvestrant concentration on day of biopsy and ER, PR, and Ki-67 
levels. Blue line represents linear regression and shaded area represents 95% CIs.   
AUC: area under the concentration–time curve; C: concentration; Cavg: average of all plasma 
concentrations; CI: confidence interval; Cmax: maximum plasma concentration; Cmin: minimum plasma 
concentration; ER: estrogen receptor; PD: pharmacodynamics; PK: pharmacokinetics; 
PR: progesterone receptor; ss: steady state 
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